Interestingly, some authors have tried to combine hematological markers, such as platelets, with CEA to further improve its prognostic efficacy in NSCLC [26], and other studies have indicated that a combination of RDW with tumor markers would be useful for the prognosis of cancer patients [27, 28]. This evidence concerns the gene CEACAM5 and neoplasm.